Pantetheine

VectivBio Announces Results of Extraordinary General Meeting

Retrieved on: 
Friday, December 9, 2022
Extraordinary general meeting, Acquisition, Respiration (physiology), MMA, Congenital disorders of amino acid metabolism, Manufacturing execution system, Degenerative disease, Short bowel syndrome, Propionic acidemia, NAMS, Community of Metros, Coenzyme A, University of Groningen, Growth, General partnership, Business administration, Pantetheine, University, Novartis, International business, Patient, SBS, Fine chemical

BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022.

Key Points: 
  • BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022.
  • Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio.
  • He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner.
  • His deep experience in life-science capital markets will benefit VectivBio as we enter our next stage of growth,” said Tom Woiwode, VectivBio Board Chairman.

VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, EST, MMA, Short bowel syndrome, Proxy, Propionic acidemia, SBS, Federal Council (Switzerland), Degenerative disease, Patient, Exercise, Respiration (physiology), Manufacturing execution system, Security (finance), Extraordinary general meeting, Congenital disorders of amino acid metabolism, CET, Community of Metros, Coronavirus, Pantetheine, Coenzyme A, Holding company, Pharmaceutical industry

The sole agenda item of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors.

Key Points: 
  • The sole agenda item of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors.
  • Shareholders shall be represented at the Extraordinary General Meeting exclusively by the independent proxy.
  • For information on how to exercise rights and issue voting instructions to the independent proxy, shareholders can access the invitation to the Extraordinary General Meeting at www.edocumentview.com/VECT.
  • These statements include, but are not limited to, statements concerning the timing of the Extraordinary General Meeting.

VectivBio to Present at the 2022 Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Respiration (physiology), Coenzyme A, Propionic acidemia, SBS, Nasdaq, Congenital disorders of amino acid metabolism, Short bowel syndrome, MMA, Community of Metros, Manufacturing execution system, Conference, Patient, Degenerative disease, Pantetheine, Pharmaceutical industry

BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will be presenting at the Jefferies London Healthcare Conference on Thursday, November 17, 2022.

Key Points: 
  • BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will be presenting at the Jefferies London Healthcare Conference on Thursday, November 17, 2022.
  • VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions.
  • VectivBio is also advancing its modular, small molecule CoMET platform to address a broad range of previously undruggable Inherited Metabolic Diseases (IMDs).
  • Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA), propionic acidemia (PA), and other organic acidemias.

VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Retrieved on: 
Thursday, November 3, 2022
Patient, Pantetheine, Propionic acidemia, Compliance, Manufacturing execution system, Congenital disorders of amino acid metabolism, SBS, Respiration (physiology), Short bowel syndrome, GLOBE, FDA, Safety, PS, COVID-19, Nasdaq, Stoma, Study, Degenerative disease, STARS, Failure, U.S. Securities and Exchange Commission, Community of Metros, Forward-looking statement, Partnership, Drug development, Phrase, CIC, MMA, Security (finance), Coenzyme A, Medical imaging, Pharmaceutical industry

BASEL, Switzerland, Nov. 03, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the completion of enrollment of the Colon-in-Continuity (CIC) cohort for the company’s Phase 3 STARS (STudy of ApRglutide in SBS) pivotal study investigating the long-acting synthetic GLP-2 agonist apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF).

Key Points: 
  • This result is a testament to a successful operational effort based on our strong partnership with patients and investigators involved in this study.
  • STARS is a pivotal, global Phase 3 study enrolling approximately 144 patients with SBS-IF stratified 50/50 for CIC and stoma, with patients being evaluated over 48 weeks and 24 weeks respectively.
  • The study includes an improved PS weaning algorithm tailored to remnant bowel anatomy to enhance signal detection.
  • STARS is designed to establish a new standard of care for all patients with SBS-IF and to tailor apraglutide treatment to patients with distinct remnant bowel anatomy.

VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares

Retrieved on: 
Tuesday, October 18, 2022
808, U.S. Securities and Exchange Commission, MMA, Sale, Telephone, SEC filing, SEC, SBS, Short bowel syndrome, Coenzyme A, Nicollet Mall, LLC, Pantetheine, Jefferies Group, Risk, Patient, Manufacturing execution system, Madison Avenue, Degenerative disease, Attention, Nasdaq, Richard Driehaus, State Street, Community of Metros, Form, Propionic acidemia, Congenital disorders of amino acid metabolism, Phrase, GLOBE, Prospectus, Jefferies, Respiration (physiology), Forward-looking statement, Life insurance, Security (finance), Citadel

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share.

Key Points: 
  • BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share.
  • Before deducting the underwriting discounts and commissions and offering expenses, VectivBio received total gross proceeds of approximately $125 million.
  • Jefferies, SVB Securities and Piper Sandler acted as the joint book-running managers for the offering.
  • VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions.

VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares

Retrieved on: 
Thursday, October 13, 2022
808, U.S. Securities and Exchange Commission, MMA, Sale, Telephone, SEC filing, SEC, SBS, Short bowel syndrome, Coenzyme A, Nicollet Mall, LLC, Pantetheine, Jefferies Group, Risk, Patient, Manufacturing execution system, Madison Avenue, Degenerative disease, Attention, Nasdaq, Richard Driehaus, State Street, Community of Metros, Form, Propionic acidemia, Congenital disorders of amino acid metabolism, Phrase, GLOBE, Prospectus, Jefferies, Respiration (physiology), Forward-looking statement, Life insurance, Security (finance), Citadel

BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of an underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share.

Key Points: 
  • BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of an underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share.
  • Before deducting the underwriting discounts and commissions and offering expenses, VectivBio expects to receive total gross proceeds of approximately $125 million.
  • The offering is expected to close on or about October 17, 2022, subject to satisfaction of customary closing conditions.
  • These statements include, but are not limited to, whether VectivBio will offer the ordinary shares or consummate the offering, and the timing, size and use of proceeds of the offering described herein.

VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)

Retrieved on: 
Thursday, October 13, 2022
U.S. Securities and Exchange Commission, Colon, Nutrient, MMA, STARS, SBS, Short bowel syndrome, Population, Nutrition, Anatomy, Coenzyme A, Pantetheine, Patient, Drug development, Manufacturing execution system, Degenerative disease, Security (finance), Nasdaq, CIC, Pharmacokinetics, Community of Metros, Water, Propionic acidemia, Adult, Congenital disorders of amino acid metabolism, Safety, Phrase, GLOBE, Interim, CMO, Forward-looking statement, Respiration (physiology), Failure, PS/2 port, FDA, COVID-19, Compliance, Pharmaceutical industry, Medical imaging, PS

BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced positive interim data from the company’s ongoing Phase 2 STARS Nutrition study evaluating the safety, pharmacokinetics and efficacy of apraglutide, an investigational new drug that is a next-generation, long-acting synthetic GLP-2 agonist, in adult patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC). The STARS Nutrition clinical program is the first-ever study prospectively evaluating the clinical benefit of a GLP-2 agonist specifically in a CIC patient population. Patients with CIC anatomy represent over half of the total SBS-IF patient population and are underserved by current treatment options.

Key Points: 
  • The STARS Nutrition clinical program is the first-ever study prospectively evaluating the clinical benefit of a GLP-2 agonist specifically in a CIC patient population.
  • Patients with CIC anatomy represent over half of the total SBS-IF patient population and are underserved by current treatment options.
  • Interim data showed that six-month treatment with weekly apraglutide resulted in an average 50% reduction in PS volume and a 47% reduction in parenteral energy content.
  • In the nine patients who reached at least three months of treatment, the average PS reduction was 31% after three months of treatment.

VectivBio Announces Date of Extraordinary General Meeting of Shareholders

Retrieved on: 
Wednesday, October 12, 2022
U.S. Securities and Exchange Commission, MMA, SBS, Short bowel syndrome, Coenzyme A, Pantetheine, Patient, Manufacturing execution system, Degenerative disease, Security (finance), Coronavirus, Nasdaq, Extraordinary general meeting, Exercise, Board, Community of Metros, Propionic acidemia, CEST, Congenital disorders of amino acid metabolism, EDT, Phrase, GLOBE, Proxy, Director, Forward-looking statement, Respiration (physiology), Federal Council (Switzerland), COVID-19, Holding company, Pharmaceutical industry

The sole agenda item of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors.

Key Points: 
  • The sole agenda item of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors.
  • Shareholders shall be represented at the Extraordinary General Meeting exclusively by the independent proxy.
  • For information on how to exercise rights and issue voting instructions to the independent proxy, shareholders can access the invitation to the Extraordinary General Meeting at www.edocumentview.com/VECT .
  • These statements include, but are not limited to, statements concerning the timing of the Extraordinary General Meeting.

VectivBio Announces Closing of $54 Million Aggregate Financing

Retrieved on: 
Wednesday, June 29, 2022
808, Community of Metros, Congenital disorders of amino acid metabolism, Pantetheine, Patient, USD, Securities Act of 1933, Manufacturing execution system, Attention, Degenerative disease, SEC filing, GLOBE, Exercise, Sale, U.S. Securities and Exchange Commission, Prospectus, Telephone, State Street, Short bowel syndrome, Propionic acidemia, Form, LLC, Nasdaq, SBS, Coenzyme A, Respiration (physiology), MMA, Nicollet Mall, Security (finance), Pharmaceutical industry

All ordinary shares sold in the public offering were offered by VectivBio at a public offering price of $5.25 per share.

Key Points: 
  • All ordinary shares sold in the public offering were offered by VectivBio at a public offering price of $5.25 per share.
  • The total gross proceeds to VectivBio from the public offering, including pursuant to the underwriters option, were approximately $34 million, before deducting underwriting discounts and commissions and offering expenses.
  • All ordinary shares sold in the private placement transaction were offered by VectivBio at a price of $5.75 per ordinary share, for gross proceeds to VectivBio of approximately $20 million, before deducting financial advisory fees and other offering expenses.
  • VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions.

VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares

Retrieved on: 
Wednesday, June 15, 2022
808, Congenital disorders of amino acid metabolism, Pantetheine, Nicollet Mall, Coenzyme A, Phrase, Short bowel syndrome, Prospectus, Risk, Attention, Company, Respiration (physiology), U.S. Securities and Exchange Commission, State Street, LLC, Forward-looking statement, Securities Act of 1933, Degenerative disease, GLOBE, Manufacturing execution system, Sale, SEC, Nasdaq, Patient, Telephone, SEC filing, SBS, Form, Propionic acidemia, Community of Metros, MMA, Security (finance)

BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of a follow-on public offering of 5,715,000 ordinary shares at a public offering price of $5.25 per share for aggregate gross proceeds of approximately $30 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of a follow-on public offering of 5,715,000 ordinary shares at a public offering price of $5.25 per share for aggregate gross proceeds of approximately $30 million, before deducting underwriting discounts and commissions and offering expenses.
  • In addition, VectivBio has granted the underwriters a 30-day option to purchase up to an additional 857,250 ordinary shares at the public offering price, less the underwriting discounts and commissions.
  • The sale of these ordinary shares will not be registered under the Securities Act of 1933, as amended.
  • The weighted average price per ordinary share in the public offering and private placement is approximately $5.44 per ordinary share.